Illumina Completes $7.1B Grail Deal Amid Antitrust Scrutiny
Illumina Inc. announced Wednesday that it completed its planned $7.1 billion acquisition of Grail, a biotechnology company focused on early-detection cancer testing using DNA, even as the deal faces a legal...To view the full article, register now.
Already a subscriber? Click here to view full article